

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>	Complete if Known	
	Application Number	10/530,499
	Filing Date	April 6, 2005
	First Named Inventor	Pagé
	Art Unit	Unknown
	Examiner Name	Unknown
	Attorney Docket No.	100831-1P US
SHEET 1 of 2		

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
SA		WO 97/19063	05-29-1997	Sanofi		<input type="checkbox"/>
		WO 00/46209	08-10-2000	Sanofi-Synthelabo		<input type="checkbox"/>
		WO 02/36590	05-10-2002	Amrad Operations Pty Ltd		<input type="checkbox"/>
		WO 02/060447	08-08-2002	University of Connecticut		<input type="checkbox"/>
		WO 02/085866	10-31-2002	AstraZeneca AB		<input type="checkbox"/>
		WO 2004/035548	04-29-2004	AstraZeneca AB		<input type="checkbox"/>
		EP 0445781	09-11-1991	Sterling Drug Inc.		<input type="checkbox"/>
		FR 1481049	05-19-1967	Serge Lécolier		<input checked="" type="checkbox"/>
Examiner Signature				Date Considered	09-19-07	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/530,499
Filing Date	April 6, 2005
First Named Inventor	Pag�
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket No.	100831-1P US

SHEET 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
NA		STN International, file CAPLUS, CAPLUS accession no. 1973:87, document no. 78:87, Paglietti G. et al, "Dialkylaminoalkylbenzimidazoles of pharmacological interest", & Studi Sassaressi, Sezione 2: Archivio Bimestrale di Scienze Mediche e Naturali (1971), 49(5-6), 192-203	<input type="checkbox"/>
NA		SEKI, T. et al., "2-Benzimidazolethiol derivatives.... -5-substituted, benzimidazole", Chem. Abstracts, 1969, pg. 445, Vol. 71, No. 13, THE ABSTRACT, No. 61291h, Yakugaku Zasshi, 1969, 89 (5), 617-626	<input type="checkbox"/>
NA		PAGLIETTI, G. et al., "Dialkylaminoalkylbenzimidazoles of pharmacological interest III", Chem. Abstracts, 1972, pg. 479, Vol. 77, No. 7, THE ABSTRACT, No. 48338h, Farmaco, Ed. Sci. 1972, 27 (4), 333-342	<input type="checkbox"/>
NA		LECOLIER, S. et al., "New benzimidazoles with morphine activity", Chim. Ther., 1967, pgs 16-24, Vol. 2, No. 1	<input checked="" type="checkbox"/>
NA		BURKE, T. et al., "Probes for Narcotic Receptor Mediated Phenomena. 7. ¹ Synthesis and Pharmacological Properties of Irreversible Ligands Specific for μ or δ Opiate Receptors", J. Med. Chem., 1984, pgs. 1570-1574, Vol. 27	<input type="checkbox"/>
NA		SMITH, J. et al., "Necklace-Coded Polymer-Supported Combinatorial Synthesis of 2-Arylamino benzimidazoles", J. Comb. Chem., 1999, pgs. 368-370, Vol. 1	<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
Examiner Signature	[Signature]		Date Considered 09-17-07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.